Abstract: The present invention provides a method for producing condensation aerosols for the treatment of disease and/or chronic, intermittent or acute conditions. These condensation aerosols are produced from drugs including temperature sensitive drugs and small molecule drugs that are coated onto a foil substrate which is heated via electrical resistance heating at precisely controlled temperature profiles with controllable ramp-up and heating rates to vaporize the coated drug which subsequently condenses to form aerosol particles. These condensation aerosols have little or no degradation products. Kits comprising a drug and a device for producing a condensation aerosol are also provided. Also disclosed, are methods for using these aerosols and kits and methods of making the aerosols.

Abstract: The present invention provides a method for producing condensation aerosols for the treatment of disease and/or chronic, intermittent or acute conditions. These condensation aerosols are produced from drugs including temperature sensitive drugs and small molecule drugs that are coated onto a foil substrate which is heated via electrical resistance heating at precisely controlled temperature profiles with controllable ramp-up and heating rates to vaporize the coated drug which subsequently condenses to form aerosol particles. These condensation aerosols have little or no degradation products. Kits comprising a drug and a device for producing a condensation aerosol are also provided. Also disclosed, are methods for using these aerosols and kits and methods of making the aerosols.

Abstract: The present invention provides microfluidic devices that comprise a body structure comprising at least a first microscale channel network disposed therein. The body structure has a plurality of ports or wells disposed in the body structure, where each port is in fluid communication with one or more channels in the first channel network. The devices also include a cover layer comprising a plurality of apertures disposed through the cover layer. The cover layer is mated with the body structure whereby each of the apertures is aligned with a separate one of the plurality of ports. First and second rings are preferentially disposed between the cover layer and the body structure and located circumferentially around each of the apertures of the cover layer. An annular groove is also preferentially disposed between the ring structures to help further minimize the leakage of adhesive or other bonding material into the ports or wells of the device when the cover layer is mated to the body structure.

Abstract: The present invention provides microfluidic devices that comprise a body structure comprising at least a first microscale channel network disposed therein. The body structure has a plurality of ports or wells disposed in the body structure, where each port is in fluid communication with one or more channels in the first channel network. The devices also include a cover layer comprising a plurality of apertures disposed through the cover layer. The cover layer is mated with the body structure whereby each of the apertures is aligned with a separate one of the plurality of ports. First and second rings are preferentially disposed between the cover layer and the body structure and located circumferentially around each of the apertures of the cover layer. An annular groove is also preferentially disposed between the ring structures to help further minimize the leakage of adhesive or other bonding material into the ports or wells of the device when the cover layer is mated to the body structure.

Abstract: This invention provides rate controlling membranes for controlled drug delivery devices that are stable over time and exhibit more predictable and consistent membrane functionality. According to another aspect, the membranes have enhanced permeability. According to the invention, the rate controlling membrane of a controlled drug delivery device is subjected to a pre-treatment annealing process wherein it is subjected to an elevated temperature for a predetermined time period and subsequently cooled to ambient conditions before incorporation into a controlled drug delivery device.

Abstract: This invention provides rate controlling membranes for controlled drug delivery devices that are stable over time and exhibit more predictable and consistent membrane functionality. According to another aspect, the membranes have enhanced permeability. According to the invention, the rate controlling membrane of a controlled drug delivery device is subjected to a pre-treatment annealing process wherein it is subjected to an elevated temperature for a predetermined time period and subsequently cooled to ambient conditions before incorporation into a controlled drug delivery device.